Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DS 1040

Next Previous
Drug Profile

DS 1040

Alternative Names: DS-1040b; DS1040

Latest Information Update: 30 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antithrombotics; Cardiovascular therapies
  • Mechanism of Action Carboxypeptidase U inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Pulmonary embolism; Stroke

Most Recent Events

  • 28 Aug 2020 No recent reports of development identified for phase-I development in Stroke in Japan (IV, Infusion)
  • 19 Jan 2020 Daiichi Sankyo completes phase I clinical trials in Stroke in Japan (IV) (JapicCTI-173612) (NCT03198715)
  • 05 Aug 2019 Daiichi Sankyo completes a phase-I/II clinical trial in Pulmonary embolism (Adjunctive treatment, In the elderly, In adults) in Spain, Netherlands, Italy, Germany, France, France, Belgium, USA and Austria (IV) (NCT02923115)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top